Christopher J. Shepherd

Author

Also Known As

C J Shepherd, C. Shepherd, C.J. Shepherd, Christopher J Shepherd, Christopher J. Shepherd, Christopher Shepherd, Sarah Scott

Publications

787

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research AstraZeneca (United Kingdom)The University of Texas MD Anderson Cancer Center

About

Christopher J. Shepherd is an author at Institute of Cancer Research specializing in medicine, cellular physiology, and allergy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	57
2	Health Sciences	1	1	28
3	Natural Sciences	1	1	15
4	Allergy	1	1	15
5	Cell Biology	1	1	14

Christopher J. Shepherd

Publications

584

Citations

H-Index

Page 1

	Year	Citations
Distinct roles for miR‐1 and miR‐133a in the proliferation and differentiation of rhabdomyosarcoma cells Prakash K. Rao, Edoardo Missiaglia, Lauren Shields, The FASEB Journal	2010	130
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer Peter Schmid, Catherine Harper‐Wynne, M. Ferreira, JAMA Oncology	2019	90
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer J F Knight, Christopher J. Shepherd, Siân Rizzo, British Journal of Cancer	2008	89
Expression profiling of CD133<sup>+</sup> and CD133<sup>—</sup> epithelial cells from human prostate Christopher J. Shepherd, Siân Rizzo, Ioanna Ledaki, The Prostate	2008	65
Assessment of deep learning-based reconstruction on T2-weighted and diffusion-weighted prostate MRI image quality Kang‐Lung Lee, Dimitri A. Kessler, Simon Dezonie, European Journal of Radiology	2023	57
Both Fcγ and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions<i>in vitro</i> A. L. Hepburn, Justin C. Mason, S Wang, Clinical & Experimental Immunology	2006	48
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance Timothy A. Yap, Patricia LoRusso, Deborah J. Wong, Clinical Cancer Research	2022	48
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. Shannon N. Westin, Jennifer K. Litton, Rochelle A Williams, Journal of Clinical Oncology Parp InhibitorBreast OncologyMolecular MarkersGynecologyPharmacotherapy	2018	28
Acute-Phase Proteins and the Serological Evaluation of Experimental Contact Sensitivity in the Mouse Ian Kimber, R.K. Ward, Christopher J. Shepherd, International Archives of Allergy and Immunology Immunocytochemical TechniqueLaboratory ImmunologyImmunologyMolecular BiologyAcute-phase Proteins	1989	15
A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation Bernadette Daly-Burns, Tahirah N. Alam, Alan Mackay, Differentiation Lineage PlasticityUrologyCell DivisionCell Line ModelCell Proliferation	2006	14

Page 1